MarketCapExport financials
Guardion Health Sciences (GHSI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Guardion Health Sciences Income Statement 2023-2011 | GHSI
Brief overview of income trends at Guardion Health Sciences
The conclusions below are based on five years of reported results. Guardion Health Sciences reported revenue of $942 thousand in 2018 and $12.2 million by 2023. Overall revenue changed by +1200.1%, equal to an annualized rate of about 67%. The annual growth rate indicates an exceptionally strong top-line trend.
At the gross-profit level, the result moved from 544 thousand dollars to 5.4 million dollars, a change of +891.7%. Costs absorbed a larger share of revenue over the period. The gross margin was 57.7% at the start and 44% at the end. The margin decline reflects a less favorable sales-and-cost structure.
Over the period, EBITDA shifted from −$6.1 million to −$4.3 million, a change of +28.8%. EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of −643.5% and −35.2%. The increased EBITDA share is a positive sign.
Across the five years, the net result shifted from −$7.8 million to $158 thousand. The trajectory reversed from a loss to positive earnings.
Conclusion
The five-year picture requires weighing both strengths and weaknesses. Key strengths include revenue expansion, higher operating efficiency and net-income growth. The weaker side of the profile includes weaker gross profitability and limited operating profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Guardion Health Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 7.1 M | 307 K | 35.5 M | 8.02 M | - | - | - | - | - | - | - | - |
Shares |
1.27 M | 1.12 M | 474 K | 14.3 M | 6.08 M | 20.2 M | 13.9 M | 21.8 M | 16.4 M | - | - | - | - |
Historical Prices |
- | 6.33 | 0.647 | 2.49 | 1.32 | - | - | - | - | - | - | - | - |
Net Income |
158 K | -14.9 M | -24.7 M | -8.57 M | -10.9 M | -7.77 M | -5.31 M | -5.75 M | -3.75 M | - | - | - | - |
Revenue |
12.2 M | 11 M | 7.23 M | 1.89 M | 903 K | 942 K | 437 K | 141 K | 113 K | - | - | - | - |
Cost of Revenue |
6.85 M | 6.53 M | 4.12 M | 1.95 M | 341 K | 398 K | 175 K | 75.7 K | 50.1 K | - | - | - | - |
Gross Profit |
5.39 M | 4.52 M | 3.11 M | -56.8 K | 562 K | 544 K | 262 K | 65.3 K | 62.7 K | - | - | - | - |
Operating Income |
-4.34 M | -17.4 M | -24.7 M | -8.55 M | -10.5 M | -6.14 M | -5.28 M | -3.95 M | -6.39 M | - | - | - | - |
Interest Expense |
- | - | - | 7.27 K | 258 K | 2.29 K | 23.7 K | 1.1 M | 753 K | - | - | - | - |
EBITDA |
-4.32 M | -16.2 M | -24 M | -8.49 M | -10.4 M | -6.06 M | -5.16 M | -3.89 M | -6.33 M | - | - | - | - |
Operating Expenses |
9.73 M | 21.9 M | 27.9 M | 8.49 M | 11.1 M | 6.69 M | 5.54 M | 4.01 M | 6.45 M | - | - | - | - |
General and Administrative Expenses |
7.48 M | 9.58 M | 11.2 M | 7.45 M | 7.43 M | 4.93 M | 4.68 M | 3.34 M | 5.61 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Guardion Health Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.28 M | 1.28 M | 1.28 M | 1.27 M | 1.27 M | 1.27 M | 1.27 M | 61.6 M | 61.6 M | 39.2 M | 24.4 M | 24.4 M | 24.4 M | 21.4 M | 15.2 M | 88.3 M | 86.6 M | 78.6 M | 12.5 M | 36 M | 22.5 M | 20.7 M | 20.6 M | 40.3 M | 40.3 M | 40.3 M | 20.1 M | 25.8 M | 25.5 M | 24.8 M | 24.7 M | 21.4 M | 21.3 M | 21 M | 21.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
10.3 M | -4.75 M | - | 373 K | -1.17 M | 533 K | - | -1.7 M | -1.7 M | -2.62 M | - | -3.01 M | -4.54 M | -2.67 M | - | -2.14 M | -707 K | -2.35 M | - | -2.39 M | -3.05 M | -1.39 M | - | -2.15 M | -1.81 M | -2.33 M | - | -1.58 M | -856 K | -669 K | - | -1.14 M | -1.35 M | -949 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
72.9 K | 3 M | - | 3.34 M | 2.79 M | 3.19 M | - | 2.66 M | 3.28 M | 2.38 M | - | 3.15 M | 1.22 M | 233 K | - | 253 K | 1.19 M | 246 K | - | 161 K | 261 K | 243 K | - | 294 K | 221 K | 193 K | - | 62.7 K | 60 K | 55.9 K | - | 33.7 K | 29.4 K | 29.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
36.6 K | 1.82 M | - | 1.88 M | 1.54 M | 1.85 M | - | 1.58 M | 1.88 M | 1.29 M | - | 1.76 M | 665 K | 133 K | - | 114 K | 645 K | 109 K | - | 71 K | 97.1 K | 93.5 K | - | 125 K | 87.8 K | 79.3 K | - | 30.1 K | 29.7 K | 22.6 K | - | 23 K | 12.9 K | 14.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
36.3 K | 1.18 M | - | 1.46 M | 1.25 M | 1.34 M | - | 1.09 M | 1.4 M | 1.1 M | - | 1.39 M | 559 K | 100 K | - | 139 K | 546 K | 137 K | - | 90.2 K | 164 K | 149 K | - | 169 K | 133 K | 114 K | - | 32.6 K | 30.3 K | 33.3 K | - | 10.7 K | 16.5 K | 14.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-1.38 M | -1.55 M | - | -773 K | -1.01 M | -1.46 M | - | -1.74 M | -1.71 M | -2.62 M | - | -3.02 M | -4.54 M | -2.67 M | - | -2.15 M | -708 K | -2.34 M | - | -2.41 M | -2.81 M | -1.18 M | - | -1.14 M | -1.31 M | -2.33 M | - | -1.58 M | -854 K | -653 K | - | -861 K | -993 K | -723 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | 14 | 1.79 K | 1.75 K | - | 3.72 K | 1.79 K | 1.75 K | - | 4.2 K | 234 K | 17.6 K | - | 545 | 710 | 835 | - | 2.46 K | 1.92 K | 16.4 K | - | 280 K | 357 K | 226 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-1.37 M | -1.55 M | - | -758 K | -1 M | -1.46 M | - | -793 K | -1.08 M | -2.3 M | - | -2.56 M | -4.4 M | -2.65 M | - | -2.11 M | -662 K | -2.31 M | - | -2.36 M | -2.78 M | -1.17 M | - | -918 K | -1.17 M | -2.26 M | - | -1.53 M | -822 K | -637 K | - | -817 K | -974 K | -714 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
1.42 M | 2.73 M | - | 2.23 M | 2.26 M | 2.8 M | - | 2.83 M | 3.11 M | 3.72 M | - | 4.4 M | 5.1 M | 2.77 M | - | 2.29 M | 1.25 M | 2.47 M | - | 2.5 M | 2.98 M | 1.33 M | - | 1.31 M | 1.45 M | 2.45 M | - | 1.61 M | 884 K | 686 K | - | 872 K | 1.01 M | 738 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
1.4 M | 1.83 M | - | 1.9 M | 1.77 M | 2.14 M | - | 2.23 M | 2.63 M | 3.02 M | - | 3.3 M | 2.54 M | 2.29 M | - | 2.07 M | 1.71 M | 1.95 M | - | 2.02 M | 2.49 M | 948 K | - | 1.06 M | 1.03 M | 1.68 M | - | 1.39 M | 767 K | 599 K | - | 765 K | 893 K | 624 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Guardion Health Sciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Russia
Niderland
France
Israel
Australia
Danmark
